Literature DB >> 23053144

Multicenter evaluation of different target volume delineation concepts in pediatric Hodgkin's lymphoma. A case study.

C Lütgendorf-Caucig1, I Fotina, E Gallop-Evans, L Claude, J Lindh, T Pelz, B Knäusl, D Georg, R Pötter, K Dieckmann.   

Abstract

BACKGROUND AND
PURPOSE: In pediatric Hodgkin's lymphoma (PHL) improvements in imaging and multiagent chemotherapy have allowed for a reduction in target volume. The involved-node (IN) concept is being tested in several treatment regimens for adult Hodgkin's lymphoma. So far there is no consensus on the definition of the IN. To improve the reproducibility of the IN, we tested a new involved-node-level (INL) concept, using defined anatomical boundaries as basis for target delineation. The aim was to evaluate the feasibility of IN and INL concepts for PHL in terms of interobserver variability. PATIENTS AND METHODS: The INL concept was defined for the neck and mediastinum by the PHL Radiotherapy Group based on accepted concepts for solid tumors. Seven radiation oncologists from six European centers contoured neck and mediastinal clinical target volumes (CTVs) of 2 patients according to the IN and the new INL concepts. The median CTVs, coefficient of variation (COV), and general conformity index (CI) were assessed. The intraclass correlation coefficient (ICC) for reliability of delineations was calculated.
RESULTS: All observers agreed that INL is a feasible and practicable delineation concept resulting in stronger interobserver concordance than the IN (mediastinum CI(INL) = 0.39 vs. CI(IN) = 0.28, neck left CI(INL) = 0.33; CI(IN) = 0.18; neck right CI(INL) = 0.24, CI(IN) = 0.14). The COV showed less dispersion and the ICC indicated higher reliability of contouring for INL (ICC(INL) = 0.62, p < 0.05) as for IN (ICC(IN) = 0.40, p < 0.05).
CONCLUSION: INL is a practical and feasible alternative to IN resulting in more homogeneous target delineation, and it should be therefore considered as a future target volume concept in PHL.

Entities:  

Mesh:

Year:  2012        PMID: 23053144     DOI: 10.1007/s00066-012-0182-4

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  28 in total

1.  CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines.

Authors:  Vincent Grégoire; Peter Levendag; Kian K Ang; Jacques Bernier; Marijel Braaksma; Volker Budach; Cliff Chao; Emmanuel Coche; Jay S Cooper; Guy Cosnard; Avraham Eisbruch; Samy El-Sayed; Bahman Emami; Cai Grau; Marc Hamoir; Nancy Lee; Philippe Maingon; Karin Muller; Hervé Reychler
Journal:  Radiother Oncol       Date:  2003-12       Impact factor: 6.280

2.  Geometrical uncertainties, radiotherapy planning margins, and the ICRU-62 report.

Authors:  Joep C Stroom; Ben J M Heijmen
Journal:  Radiother Oncol       Date:  2002-07       Impact factor: 6.280

3.  [Radiotherapeutic quality assurance in the Hodgkin's disease study HD4 supported by the BMFT (Bundesministerium für Forschung und Technologie)].

Authors:  S L Roth; E Dühmke; H Kirschner; N Willich; R P Müller; A Bleher; M Pfreundschuh; M Löffler; V Diehl
Journal:  Strahlenther Onkol       Date:  1990-09       Impact factor: 3.621

4.  CT-based definition of thoracic lymph node stations: an atlas from the University of Michigan.

Authors:  Olivier Chapet; Feng-Ming Kong; Leslie E Quint; Andrew C Chang; Randall K Ten Haken; Avraham Eisbruch; James A Hayman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-01       Impact factor: 7.038

5.  Involved-node radiotherapy to the mediastinum.

Authors:  Suresh Senan; Anna Piet; Frank Lagerwaard
Journal:  Radiother Oncol       Date:  2006-11-27       Impact factor: 6.280

6.  Interobserver variability of clinical target volume delineation in supra-diaphragmatic Hodgkin's disease: a multi-institutional experience.

Authors:  Domenico Genovesi; Giampiero Ausili Cèfaro; Annamaria Vinciguerra; Antonietta Augurio; Monica Di Tommaso; Rita Marchese; Umberto Ricardi; Andrea Riccardo Filippi; Theodore Girinsky; Katiuscia Di Biagio; Maurizio Belfiglio; Enza Barbieri; Vincenzo Valentini
Journal:  Strahlenther Onkol       Date:  2011-05-16       Impact factor: 3.621

7.  Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study.

Authors:  Christine Mauz-Körholz; Dirk Hasenclever; Wolfgang Dörffel; Kathrin Ruschke; Tanja Pelz; Antje Voigt; Martina Stiefel; Melanie Winkler; Constanze Vilser; Karin Dieckmann; Jonas Karlén; Eva Bergsträsser; Alexander Fosså; Georg Mann; Michael Hummel; Wolfram Klapper; Harald Stein; Dirk Vordermark; Regine Kluge; Dieter Körholz
Journal:  J Clin Oncol       Date:  2010-07-12       Impact factor: 44.544

8.  Feasibility of CBCT-based target and normal structure delineation in prostate cancer radiotherapy: multi-observer and image multi-modality study.

Authors:  Carola Lütgendorf-Caucig; Irina Fotina; Markus Stock; Richard Pötter; Gregor Goldner; Dietmar Georg
Journal:  Radiother Oncol       Date:  2010-12-20       Impact factor: 6.280

9.  Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook.

Authors:  W Dörffel; H Lüders; U Rühl; M Albrecht; H Marciniak; R Parwaresch; R Pötter; G Schellong; E-W Schwarze; L Wickmann
Journal:  Klin Padiatr       Date:  2003 May-Jun       Impact factor: 1.349

10.  Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size.

Authors:  Belinda A Campbell; Nick Voss; Tom Pickles; James Morris; Randy D Gascoyne; Kerry J Savage; Joseph M Connors
Journal:  J Clin Oncol       Date:  2008-10-06       Impact factor: 44.544

View more
  6 in total

1.  Can treatment of pediatric Hodgkin's lymphoma be improved by PET imaging and proton therapy?

Authors:  B Knäusl; C Lütgendorf-Caucig; J Hopfgartner; K Dieckmann; L Kurch; T Pelz; R Pötter; D Georg
Journal:  Strahlenther Onkol       Date:  2012-11-18       Impact factor: 3.621

2.  Delineation of the larynx as organ at risk in radiotherapy: a contouring course within "Rete Oncologica Piemonte-Valle d'Aosta" network to reduce inter- and intraobserver variability.

Authors:  Domenico Cante; Edoardo Petrucci; Cristina Piva; Valeria Casanova Borca; Piera Sciacero; Maurizio Bertodatto; Caterina Marta; Pierfrancesco Franco; Monica Viale; Giovanni La Valle; Maria Rosa La Porta; Oscar Bertetto
Journal:  Radiol Med       Date:  2016-07-15       Impact factor: 3.469

Review 3.  Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma: when should they be considered and which questions remain open?

Authors:  Frank Lohr; Dietmar Georg; Luca Cozzi; Hans Theodor Eich; Damien C Weber; Julia Koeck; Barbara Knäusl; Karin Dieckmann; Yasser Abo-Madyan; Christian Fiandra; Rolf-Peter Mueller; Andreas Engert; Umberto Ricardi
Journal:  Strahlenther Onkol       Date:  2014-09-11       Impact factor: 3.621

4.  Does ultrasound provide any added value in breast contouring for radiotherapy after conserving surgery for cancer?

Authors:  Cynthia Aristei; Isabella Palumbo; Lorenzo Falcinelli; Rossana Crisci; Laura Cardinali; Barbara Palumbo; Valentina Lancellotta; Giampaolo Montesi; Gianni Gobbi; Claudio Zucchetti; Vittorio Bini
Journal:  Radiat Oncol       Date:  2015-08-22       Impact factor: 3.481

5.  Modelling tumour volume variations in head and neck cancer: contribution of magnetic resonance imaging for patients undergoing induction chemotherapy.

Authors:  N Dinapoli; T Tartaglione; F Bussu; R Autorino; F Miccichè; M Sciandra; E Visconti; C Colosimo; G Paludetti; V Valentini
Journal:  Acta Otorhinolaryngol Ital       Date:  2017-02       Impact factor: 2.124

6.  A dose based approach for evaluation of inter-observer variations in target delineation.

Authors:  Ingrid Kristensen; Kristina Nilsson; Måns Agrup; Karin Belfrage; Anna Embring; Hedda Haugen; Anna-Maja Svärd; Tommy Knöös; Per Nilsson
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2017-11-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.